Regeneron Pharmaceuticals, Inc. REGN
Healthcare · Biotechnology · United States · S&P 500
Based on the available data, Regeneron Pharmaceuticals, Inc. gets an algorithmic score of 72/100. It trades at 750.51 $, with a bullish technical trend (RSI 37.3) and 33.3% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High net margin (27.9%): pricing power / competitive advantage.
- Low-debt balance sheet.
- Low beta (0.33): defensive profile.
- Meaningful dividend (50.00%).
Weaknesses
- —
Fundamentals
| P/E | 18.62 |
| Forward P/E | 12.33 |
| PEG | 1.32 |
| P/B | 2.37 |
| EV/EBITDA | 14.81 |
| P/S | 4.97 |
| ROE % | 14.04 |
| ROA % | 6.53 |
| Gross margin % | 44.46 |
| Operating margin % | 33.11 |
| Net margin % | 27.87 |
| Revenue growth % (y/y) | 16.70 |
| Earnings growth % (y/y) | -4.50 |
| Revenue CAGR % | 5.62 |
| Earnings CAGR % | 1.26 |
| Debt/Equity % | 8.54 |
| Current ratio | 3.33 |
| FCF yield % | 4.87 |
| Dividend yield % | 50.00 |
| Payout % | 9.01 |
Returns
| 1 month | -5.5 % |
| 3 months | +20.5 % |
| 6 months | +0.4 % |
| YTD | -3.0 % |
| 1 year | +33.8 % |
| 3 years | -8.2 % |
| 5 years | +17.1 % |
Risk
| 1-year volatility | 33.3 % |
| Beta | 0.33 |
| 5-year max drawdown | -59.7 % |
| Sharpe 1A | 0.92 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.